Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients
Liraglutide is a long-acting glucagon-like peptide-1 receptor agonist prescribed to diabetic patients for glycaemic control. To understand the impact of liraglutide in the real-world setting, this study analysed its effects in a Portuguese cohort of Type 2 diabetes patients. This was an observationa...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/12/11/1121 |
| _version_ | 1797464597662269440 |
|---|---|
| author | José Silva-Nunes Edite Nascimento Joana Louro Jorge Dores Teresa Laginha Ana Gonçalves-Ferreira Marta Alves Selma B. Souto Nelson Cunha Elsa Pina Rui Duarte João Filipe Raposo |
| author_facet | José Silva-Nunes Edite Nascimento Joana Louro Jorge Dores Teresa Laginha Ana Gonçalves-Ferreira Marta Alves Selma B. Souto Nelson Cunha Elsa Pina Rui Duarte João Filipe Raposo |
| author_sort | José Silva-Nunes |
| collection | DOAJ |
| description | Liraglutide is a long-acting glucagon-like peptide-1 receptor agonist prescribed to diabetic patients for glycaemic control. To understand the impact of liraglutide in the real-world setting, this study analysed its effects in a Portuguese cohort of Type 2 diabetes patients. This was an observational, multicentric, and retrospective study that included 191 liraglutide-treated patients with at least 12 months of treatment. Patients’ data were collected and analysed during a 24-month follow-up period. Overall, liraglutide treatment effectively reduced HbA1c levels from 8.3% to around 7.5%, after 6, 12, and 24 months (<i>p</i> < 0.001). In fact, 38.2%, 37.2%, and 44.8% of patients at 6, 12, and 24 months, respectively, experienced an HbA1c reduction of at least 1%. Moreover, a persistent reduction in anthropometric features was also observed, with 44.0%, 47.6%, and 54.4% of patients achieving a weight reduction of at least 3% at 6, 12, and 24 months, respectively. Finally, significant improvements were observed in the HDL-c and LDL-c levels. Our results demonstrate that liraglutide effectively promoted the reduction of HbA1c values during routine clinical practice, which was sustained throughout the study. In addition, there were significant improvements in anthropometric parameters and other cardiovascular risk factors. |
| first_indexed | 2024-03-09T18:09:28Z |
| format | Article |
| id | doaj.art-fd91d45e07824af3aa7d57cf4dd6d27d |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-09T18:09:28Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-fd91d45e07824af3aa7d57cf4dd6d27d2023-11-24T09:13:21ZengMDPI AGMetabolites2218-19892022-11-011211112110.3390/metabo12111121Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese PatientsJosé Silva-Nunes0Edite Nascimento1Joana Louro2Jorge Dores3Teresa Laginha4Ana Gonçalves-Ferreira5Marta Alves6Selma B. Souto7Nelson Cunha8Elsa Pina9Rui Duarte10João Filipe Raposo11Department of Endocrinology, Diabetes and Metabolism, Curry Cabral Hospital—Centro Hospitalar Universitário de Lisboa Central, 1050-099 Lisboa, PortugalDepartment of Internal Medicine, Centro Hospitalar Tondela-Viseu, 3504-509 Viseu, PortugalDepartment of Internal Medicine, Centro Hospitalar do Oeste, 2500-176 Caldas da Rainha, PortugalDepartment of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário do Porto, 4099-001 Porto, PortugalDiabetes Clinic, Associação Protetora dos Diabéticos de Portugal (APDP), 1250-189 Lisboa, PortugalDepartment of Endocrinology, Diabetes and Metabolism, Garcia de Orta Hospital, 2805-267 Almada, PortugalDepartment of Endocrinology, Diabetes and Metabolism, Hospital de Braga, 4710-243 Braga, PortugalDepartment of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário do Porto, 4099-001 Porto, PortugalDepartment of Endocrinology, Diabetes and Metabolism, Centro Hospitalar e Universitário de Coimbra, 3000-075 Coimbra, PortugalDepartment of Internal Medicine, Centro Hospitalar Universitário do Algarve, 8000-386 Faro, PortugalDiabetes Clinic, Associação Protetora dos Diabéticos de Portugal (APDP), 1250-189 Lisboa, PortugalNOVA Medical School, New University of Lisbon, 1169-056 Lisboa, PortugalLiraglutide is a long-acting glucagon-like peptide-1 receptor agonist prescribed to diabetic patients for glycaemic control. To understand the impact of liraglutide in the real-world setting, this study analysed its effects in a Portuguese cohort of Type 2 diabetes patients. This was an observational, multicentric, and retrospective study that included 191 liraglutide-treated patients with at least 12 months of treatment. Patients’ data were collected and analysed during a 24-month follow-up period. Overall, liraglutide treatment effectively reduced HbA1c levels from 8.3% to around 7.5%, after 6, 12, and 24 months (<i>p</i> < 0.001). In fact, 38.2%, 37.2%, and 44.8% of patients at 6, 12, and 24 months, respectively, experienced an HbA1c reduction of at least 1%. Moreover, a persistent reduction in anthropometric features was also observed, with 44.0%, 47.6%, and 54.4% of patients achieving a weight reduction of at least 3% at 6, 12, and 24 months, respectively. Finally, significant improvements were observed in the HDL-c and LDL-c levels. Our results demonstrate that liraglutide effectively promoted the reduction of HbA1c values during routine clinical practice, which was sustained throughout the study. In addition, there were significant improvements in anthropometric parameters and other cardiovascular risk factors.https://www.mdpi.com/2218-1989/12/11/1121liraglutidereal-world evidencetype 2 diabetesglycaemic controlanthropometric parameterscardiovascular risk factors |
| spellingShingle | José Silva-Nunes Edite Nascimento Joana Louro Jorge Dores Teresa Laginha Ana Gonçalves-Ferreira Marta Alves Selma B. Souto Nelson Cunha Elsa Pina Rui Duarte João Filipe Raposo Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients Metabolites liraglutide real-world evidence type 2 diabetes glycaemic control anthropometric parameters cardiovascular risk factors |
| title | Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients |
| title_full | Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients |
| title_fullStr | Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients |
| title_full_unstemmed | Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients |
| title_short | Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients |
| title_sort | liraglutide effectiveness in type 2 diabetes insights from a real world cohort of portuguese patients |
| topic | liraglutide real-world evidence type 2 diabetes glycaemic control anthropometric parameters cardiovascular risk factors |
| url | https://www.mdpi.com/2218-1989/12/11/1121 |
| work_keys_str_mv | AT josesilvanunes liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients AT editenascimento liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients AT joanalouro liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients AT jorgedores liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients AT teresalaginha liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients AT anagoncalvesferreira liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients AT martaalves liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients AT selmabsouto liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients AT nelsoncunha liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients AT elsapina liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients AT ruiduarte liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients AT joaofiliperaposo liraglutideeffectivenessintype2diabetesinsightsfromarealworldcohortofportuguesepatients |